Jay Chadokiya

This study establishes patient-derived melanoma organoids (PDMOs) that retain tumor-immune heterogeneity and show context-dependent responses to immune checkpoint blockade.

This paper introduces a BBB-penetrating nanoconjugate for glioblastoma treatment that modulates the PD-1/PD-L1 axis without antibodies, showing improved brain accumulation and immune activation in vitro and in vivo.

This paper uses single-cell Raman spectroscopy and machine learning to predict therapeutic response in melanoma, achieving >96% accuracy in cell line classification and 91% accuracy in patient drug resistance inference.